About the Company

A.P. Pharma, Inc. (OTCBB:APPA.OB) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery technology. The Company’s primary focus is on its lead product candidate, APF530, for the prevention of chemotherapy-induced nausea and vomiting (CINV). A.P. Pharma received a Complete Response Letter on the APF530 NDA and is targeting the resubmission of the NDA in mid-2012. The Company has additional clinical and preclinical stage programs in the area of pain management, all of which utilize its bioerodible injectable and implantable delivery systems.

Recent Press Releases

05/10/12 - A.P. Pharma Announces First Quarter 2012 Financial Results and Recent Corporate Progress

03/26/12 - APF530 Thorough QT Study Showed No Effect on Cardiac Repolarization

03/26/12 - A.P. Pharma Announces Fourth Quarter and Full Year 2011 Financial Results and Provides Update on APF530

More Releases >>